Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma-Reference-Cited by-同舟云学术

Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma

Published:2024-07 Issue:1 Volume:118 Page:130-140
ISSN:0003-4975
Container-title:The Annals of Thoracic Surgery
language:en
Short-container-title:The Annals of Thoracic Surgery

Author:

Fick Cameron N.,Dunne Elizabeth G.,Sihag Smita,Molena Daniela,Cytryn Samuel L.,Janjigian Yelena Y.,Wu Abraham J.,Worrell Stephanie G.,Hofstetter Wayne L.,Jones David R.,Gray Katherine D.

Funder

National Institutes of Health

U.S. Department of Defense

National Cancer Institute

Publisher

Elsevier BV

Reference69 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Preoperative chemoradiotherapy for esophageal or junctional cancer;van Hagen;N Engl J Med,2012

3. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

4. Increasing cure rates of solid tumors by immune checkpoint inhibitors;Ma;Exp Hematol Oncol,2023

5. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study;Sun;Lancet,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and considerations in interpreting the age-dependent benefit of neoadjuvant treatment for adenocarcinoma of the esophagus and gastroesophageal junction;International Journal of Surgery;2024-05-10